Atika Capital Management LLC Has $5.67 Million Stake in DBV Technologies S.A. $DBVT

Atika Capital Management LLC boosted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 31.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 271,300 shares of the company’s stock after buying an additional 64,419 shares during the period. Atika Capital Management LLC owned approximately 0.49% of DBV Technologies worth $5,667,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DBVT. GAMMA Investing LLC lifted its stake in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares during the last quarter. Truvestments Capital LLC increased its stake in shares of DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the last quarter. Allworth Financial LP acquired a new position in shares of DBV Technologies during the 4th quarter worth $32,000. Royal Bank of Canada acquired a new position in shares of DBV Technologies during the 4th quarter worth $34,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of DBV Technologies during the 4th quarter worth $115,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DBVT. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Guggenheim reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $13.86 on Friday. DBV Technologies S.A. has a 1 year low of $8.51 and a 1 year high of $26.18. The business’s 50-day moving average is $16.67 and its 200-day moving average is $19.33. The company has a market capitalization of $820.65 million, a price-to-earnings ratio of -3.95 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.90 million. Analysts anticipate that DBV Technologies S.A. will post -2.05 EPS for the current year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.